InMed Pharmaceuticals (INM) EBT Margin (2021 - 2025)
InMed Pharmaceuticals (INM) posted quarterly EBT Margin of 247.29% for Q4 2025, down 1566.0% year-over-year from 16.87% in Q4 2024, and down 60.4% quarter-over-quarter from 154.17% in Q3 2025.
InMed Pharmaceuticals (INM) EBT Margin (2021 - 2025) Analysis & Trends
InMed Pharmaceuticals' EBT Margin history runs 5 years deep, the most recent figure standing at 247.29% for Q4 2025.
- In Q4 2025, EBT Margin fell 1566.0% year-over-year to 247.29%; the TTM figure through Dec 2025 stood at 158.18% (up 544.0% YoY), while the FY2025 annual figure was 165.14%, up 165.0% from the prior year.
- EBT Margin for Q4 2025 stood at 247.29%, down from 154.17% in the prior quarter.
- The five-year high for EBT Margin was 14.56% in Q2 2023, with the low at 1615.6% in Q4 2021.
- The 5-year median for EBT Margin is 193.09% (2023), against an average of 423.4%.
- The sharpest annual moves came in 2023 and 2024: EBT Margin surged 151431 bps in 2023, then plunged 13590 bps in 2024.
- InMed Pharmaceuticals' EBT Margin stood at 1615.6% in 2021, then jumped by 72 bps to 446.61% in 2022, then surged by 73 bps to 119.19% in 2023, then slumped by 94 bps to 231.63% in 2024, then dropped by 7 bps to 247.29% in 2025.
- Business Quant data shows INM's EBT Margin at 247.29% in Q4 2025, 154.17% in Q3 2025, and 100.13% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.36 Mn | 1.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -247.29% |
| Sep 30, 2025 | -154.17% |
| Jun 30, 2025 | -100.13% |
| Mar 31, 2025 | -163.85% |
| Dec 31, 2024 | -231.63% |
| Sep 30, 2024 | -132.68% |
| Jun 30, 2024 | -150.47% |
| Mar 31, 2024 | -146.93% |
| Dec 31, 2023 | -119.19% |
| Sep 30, 2023 | -281.29% |
| Jun 30, 2023 | -14.56% |
| Mar 31, 2023 | -193.09% |
| Dec 31, 2022 | -446.61% |
| Sep 30, 2022 | -1,092.12% |
| Jun 30, 2022 | -1,528.88% |
| Mar 31, 2022 | -579.28% |
| Dec 31, 2021 | -1,615.60% |